Rani Therapeutics Holdings, Inc. (RANI) DCF Valuation

Valoración de DCF de Rani Therapeutics Holdings, Inc. (Rani)

US | Healthcare | Biotechnology | NASDAQ
Rani Therapeutics Holdings, Inc. (RANI) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Rani Therapeutics Holdings, Inc. (RANI) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¡Agilice su análisis y mejore la precisión con nuestra calculadora DCF (RANI)! Utilizando datos reales de Rani Therapeutics y suposiciones personalizables, esta herramienta le permite pronosticar, analizar y evaluar Rani Therapeutics Holdings, Inc. como un inversor experimentado.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 1.0 .5 2.7 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 -52.81 488.1 -100 0 -13.2 -13.2 -13.2 -13.2 -13.2
EBITDA -26.0 -16.0 -52.1 -60.9 -65.3 .0 .0 .0 .0 .0
EBITDA, % -2657.1 -3453.46 -1916.97 100 100 -20 -20 -20 -20 -20
Depreciation .6 .6 .5 1.3 .8 .0 .0 .0 .0 .0
Depreciation, % 57.61 127.49 18.29 100 100 75.18 75.18 75.18 75.18 75.18
EBIT -26.6 -16.5 -52.6 -62.2 -66.1 .0 .0 .0 .0 .0
EBIT, % -2714.71 -3580.95 -1935.26 100 100 -20 -20 -20 -20 -20
Total Cash 16.5 73.1 117.5 98.5 48.5 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .3 1.7 .0 .0 .0
Account Receivables, % 25.54 372.29 0 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 0.000102145046 0 0 100 100 40 40 40 40 40
Accounts Payable .2 .5 1.1 1.5 .6 .0 .0 .0 .0 .0
Accounts Payable, % 20.22 116.23 39.75 100 100 71.99 71.99 71.99 71.99 71.99
Capital Expenditure -1.6 -1.2 -.5 -1.6 -1.2 .0 .0 .0 .0 .0
Capital Expenditure, % -161.49 -259.74 -18.62 100 100 -43.72 -43.72 -43.72 -43.72 -43.72
Tax Rate, % 49.96 49.96 49.96 49.96 49.96 49.96 49.96 49.96 49.96 49.96
EBITAT -26.6 -16.6 -52.6 -62.3 -33.1 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -27.7 -18.3 -50.4 -62.2 -34.3 -.6 .0 .0 .0 .0
WACC, % 10.61 10.61 10.61 10.61 6.78 9.85 9.85 9.85 9.85 9.85
PV UFCF
SUM PV UFCF -.6
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -1
Net Debt 24
Equity Value -25
Diluted Shares Outstanding, MM 26
Equity Value Per Share -0.97

What You Will Get

  • Editable Forecast Inputs: Easily modify key assumptions (growth %, margins, WACC) to explore various scenarios.
  • Real-World Data: Rani Therapeutics Holdings, Inc. (RANI)’s financial data pre-loaded to facilitate your analysis.
  • Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
  • Customizable and Professional: A refined Excel model tailored to meet your valuation requirements.
  • Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.

Key Features

  • 🔍 Real-Life RANI Financials: Pre-filled historical and projected data for Rani Therapeutics Holdings, Inc. (RANI).
  • ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
  • 📊 Professional DCF Valuation: Built-in formulas calculate Rani’s intrinsic value using the Discounted Cash Flow method.
  • ⚡ Instant Results: Visualize Rani’s valuation instantly after making changes.
  • Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review Rani Therapeutics Holdings, Inc.'s (RANI) pre-filled financial data and projections.
  3. Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
  4. Step 4: Observe the DCF model update in real-time as you modify your assumptions.
  5. Step 5: Evaluate the outputs and leverage the results for your investment strategies.

Why Choose This Calculator?

  • Designed for Industry Experts: A sophisticated tool utilized by researchers, CFOs, and investment analysts.
  • Comprehensive Data: Rani Therapeutics' historical and projected financials included for precise analysis.
  • Flexible Scenario Analysis: Effortlessly model various forecasts and assumptions.
  • Concise Outputs: Automatically computes intrinsic value, NPV, and essential financial metrics.
  • User-Friendly: Step-by-step guidance simplifies the entire process.

Who Should Use This Product?

  • Investors: Evaluate Rani Therapeutics' potential before making investment decisions.
  • CFOs and Financial Analysts: Optimize valuation methodologies and validate financial forecasts.
  • Startup Founders: Understand the valuation strategies of innovative biotech companies like Rani Therapeutics.
  • Consultants: Create detailed valuation reports for clients in the healthcare sector.
  • Students and Educators: Utilize real-world examples to practice and teach valuation concepts.

What the Template Contains

  • Pre-Filled Data: Includes Rani Therapeutics Holdings, Inc.'s (RANI) historical financials and forecasts.
  • Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations tailored for Rani Therapeutics.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs specific to RANI.
  • Key Financial Ratios: Analyze Rani Therapeutics' profitability, efficiency, and leverage metrics.
  • Customizable Inputs: Easily edit revenue growth, margins, and tax rates relevant to RANI.
  • Clear Dashboard: Charts and tables summarizing key valuation results for Rani Therapeutics Holdings, Inc. (RANI).

No products were found matching.